Johnson & Johnson showed robust growth in sales and innovation in 2024, particularly in the Innovative Medicine and MedTech sectors. However, earnings were negatively impacted by STELARA biosimilars and recent acquisitions, while challenges in China and decreased margins were noted.

Company Guidance

During Johnson & Johnson's fourth quarter 2024 earnings call, the guidance for 2025 highlighted an expected operational sales growth of 3%, despite facing significant headwinds, including the introduction of U.S. biosimilars for STELARA and macroeconomic pressures in China. The company is projecting adjusted operational earnings per share growth of nearly 9%. Sales growth is anticipated to be driven by key pharmaceutical assets such as DARZALEX and ERLEADA, alongside recently launched products like CARVYKTI and TECVAYLI. MedTech growth is expected from recent acquisitions such as ShockWave and Abiomed. The 2025 guidance also factors in approximately 50 basis points of favorable impact from acquisitions and divestitures. Despite the challenges, Johnson & Johnson remains confident in its financial outlook, supported by a diversified business model and a robust innovation pipeline.

Robust Sales Growth in 2024

Johnson & Johnson reported operational sales growth of 7% for 2024, excluding the COVID-19 vaccine, with Sprabato surpassing $1 billion in annual sales. The company now has 26 platforms generating at least $1 billion in annual revenue.

Strong Performance in Innovative Medicine

Innovative Medicine sales exceeded $14 billion for the third consecutive quarter, driven by double-digit growth in key brands such as DARZALEX, CARVYKTI, and TECVAYLI. Oncology, neuroscience, and pulmonary hypertension segments showed strong growth.

Major Product Approvals and Pipeline Advancements

In 2024, J&J achieved 27 major market approvals and initiated 16 Phase III studies. Notable FDA approvals included TREMFYA for ulcerative colitis and RYBREVANT for non-small cell lung cancer.

Significant Investment in R&D and M&A

Johnson & Johnson invested approximately $50 billion in R&D and M&A in 2024, including the acquisition agreement with Intracellular Therapies, contributing to strategic growth.

MedTech Growth and Innovation

MedTech reported annual sales over $30 billion for the second year, with growth in cardiovascular and vision segments. The company launched 15 major products and acquired ShockWave in the MedTech sector.

---

Johnson & Johnson (JNJ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JNJ Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 17, 2018	2018 (Q2)	- / 2.10	1.83	14.75% (+0.27)	―	―
Oct 16, 2018	2018 (Q3)	- / 2.05	1.9	7.89% (+0.15)	―	―
Jan 22, 2019	2018 (Q4)	- / 1.97	1.74	13.22% (+0.23)	―	―
Apr 16, 2019	2019 (Q1)	- / 2.10	2.06	1.94% (+0.04)	―	―
Jul 16, 2019	2019 (Q2)	- / 2.58	2.1	22.86% (+0.48)	―	―
Oct 15, 2019	2019 (Q3)	- / 2.12	2.05	3.41% (+0.07)	―	―
Jan 22, 2020	2019 (Q4)	- / 1.88	1.97	-4.57% (-0.09)	―	―
Apr 14, 2020	2020 (Q1)	- / 2.30	2.1	9.52% (+0.20)	―	―
Jul 16, 2020	2020 (Q2)	- / 1.67	2.58	-35.27% (-0.91)	―	―
Oct 13, 2020	2020 (Q3)	- / 2.20	2.12	3.77% (+0.08)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

JNJ Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 22, 2025	$148.15	$145.27	-1.94%
Oct 15, 2024	$160.31	$162.79	+1.55%
Jul 17, 2024	$148.68	$154.16	+3.69%
Apr 16, 2024	$144.15	$141.08	-2.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---